Inhibitor Therapeutics, Inc.
INTI
$0.08
$0.0110.26%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 557.90K | 363.40K | 370.20K | 438.50K | 596.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.32M | 741.20K | 695.80K | 674.60K | 1.48M |
| Operating Income | -1.32M | -741.20K | -695.80K | -674.60K | -1.48M |
| Income Before Tax | -1.30M | -712.20K | -659.90K | -632.80K | -1.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.30M | -712.20K | -659.90K | -632.80K | -1.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.30M | -712.20K | -659.90K | -632.80K | -1.42M |
| EBIT | -1.32M | -741.20K | -695.80K | -674.60K | -1.48M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 172.57M | 172.57M | 172.57M | 172.32M | 172.32M |
| Average Diluted Shares Outstanding | 172.57M | 172.57M | 172.57M | 172.32M | 172.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |